TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy~* Baseline hemoglobin value of \<= 11 g/dL unrelated to transfusion~* Planned chemotherapy for a minimum of 12 weeks during the study~* Life expectancy of \>= 6 months~* ECOG Performance Status 0-2~Exclusion Criteria:~* Diagnosis of a myeloid malignancy or known history of myelodysplasia~* Planned non-palliative radiation during the study~* Anemia due to factors other than cancer/chemotherapy~* Prior treatment with Epoetin alfa or any other erythropoietic agent within the previous three months~* History of uncontrolled cardiac arrhythmias or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Track Health Function of the MyHealthevet Personal Health Record

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans with diagnosis of prediabetes (HbA1c 5.7-6.4%, fasting plasma glucose 100-125 mg/dL or oral glucose tolerance test 140-199 mg/dL)~* English speaking~* Access to the Internet~* Body mass index (BMI) of 25-42 kg/m and a sedentary lifestyle (not being physically active three days per week for 20 minutes each time for the previous six months and not performing regular resistance exercise)~* Able to engage in a regular program of mild-to-moderate intensity physical activity but were not currently following a weight loss diet or participating in an intervention trial~Exclusion Criteria:~* Cognitively impaired (Mini-Cog greater than or equal to 3)~* Depressed (PHQ-2 less than or equal to 3)~* Vision or hearing disorders~* Have been diagnosed with diabetes mellitus, uncontrolled hypertension, or cardiovascular disease~* Currently pregnant or nursing.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient health record (Type: EXPERIMENTAL): The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes in Neuropsychiatric Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Age 18-64~* Maximum cumulative (lifetime) antipsychotic exposure of one week, and no antipsychotic use in the previous 30 days before enrolling in the study~* No history of diabetes or other serious medical or neurological condition associated with glucose intolerance or insulin resistance (eg, Cushing disease),~* Not taking a medication associated with insulin resistance (eg, hydrochlorothiazide, furosemide, ethacrynic acid, metolazone, chlorthalidone), beta blockers, glucocorticoids, phenytoin, nicotinic acid, cyclosporine, pentamidine, or narcotics)~* No history of cocaine use in the previous 30 days, and~* No laboratory evidence of diabetes at baseline (fasting glucose \<126 mg/dL or 2-hour glucose \<200 mg/dL on a glucose tolerance test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Open Trial Group (Type: EXPERIMENTAL): The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Stroke With IpsiHand

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months post stroke~* Modified Ashworth Scale of 1+ or less of elbow flexion in the affected upper extremity~* Short Blessed Test Score of 8 or less~* Unstructured Mesulam with 2 or less omissions~Exclusion Criteria:~* Dementia~* Severe spasticity in affected upper extremity~* Unilateral Visual Inattention (neglect)~* Contracture(s) in the affected upper extremity~* Botox injections administered within 9 months~* Aphasia which limits effective communication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 88 Years
- Healthy Volunteers: t

Study Arms:
- IpsiHand (Type: EXPERIMENTAL): IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female patients, ≥50 years of age with signed informed consent before study procedures~* Visual impairment predominantly due to nAMD.~* Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by fluorescein angiography (FA) and/or color fundus photography~* Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT~* BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate Snellen equivalent of 20/32 and 20/320)~Key Exclusion Criteria:~* Any type of advanced, severe or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.~* Stroke or myocardial infarction within 3 months prior to Screening.~* Any active periocular or ocular infection or inflammation in both eyes.~* Ocular disorders in the study eye at the time of enrollment that may confound interpretation of study results and compromise visual acuity.~* Presence of amblyopia or amaurosis in the fellow eye.~* History of treatment with any anti-angiogenic drugs (including any anti- vascular endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab \[Avastin®\], aflibercept \[Eylea®\]) or vPDT in the study eye.~* History of intravitreal treatment with corticosteroids within 6 months and history of intra-ocular surgery within 3 months in the study eye prior to the Screening.~* Pregnant or nursing (lactating) women. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I ranibizumab 0.5 mg monthly (Type: ACTIVE_COMPARATOR): Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
- Group II ranibizumab 0.5 mg TER (Type: ACTIVE_COMPARATOR): Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Male or female patients aged ≥10 and \<18 years old (at least 4 patients below 16 years old).~* Body mass index (BMI) \>85th percentile for age and gender; BMI ≤50 kg/m2.~* Male and female patients with documented T2DM insufficiently controlled with metformin at a stable dose and regimen for 8 weeks prior to randomization and/or basal insulin at stable dose (± 20%) and regimen for 8 weeks prior to randomization. The exact individual metformin dose will be selected according to local regulation and to the investigator's medical judgment.~* Glycated hemoglobin (HbA1c) \>6.5% and ≤11% at screening.~Exclusion criteria:~* If female, ongoing pregnancy (defined as positive serum pregnancy test), breast-feeding.~* Sexually active postmenarchal female patient who does not agree to use an adequate and highly effective method of contraception throughout the study duration and according to local regulation (ie, hormonal contraception, condom, etc.).~* Diabetes other than T2DM.~* Fasting plasma glucose \>250 mg/dL (\>13.9 mmol/L) at screening.~* Use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin and basal insulin (eg, alpha glucosidase inhibitor, glucagon-like peptide (GLP-1) receptor agonist, dipeptidyl peptidase-IV (DPP-IV) inhibitors, short-acting insulin etc.) within 1 month prior to the screening visit.~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lixisenatide (Type: EXPERIMENTAL): Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
- Placebo (Type: PLACEBO_COMPARATOR): Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants at least 18 years old~* Participants with moderate to severe RA not previously treated with TCZ (Intravenous \[IV\] or SC) for whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in combination with another conventional synthetic disease modifying anti-rheumatic drugs (csDMARD)~Exclusion Criteria:~* Participants taking part in a clinical trial on RA at the time of inclusion~* Participants with a contra-indication to TCZ SC therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with Moderate to Severe RA (Type: None): Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurobiological Responses in Alcoholism and Early Trauma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
AUD inclusion Criteria:~* Alcohol use disorder~* Either low or high early trauma (based on the Childhood Trauma Questionnaire)~* Body mass index (BMI) up to 35 (due to weight limitations of the MRI scanner)~AUD exclusion Criteria:~* Current or past substance use disorder other than alcohol; excluding caffeine and nicotine~* Psychiatric disorders except for mood and anxiety disorders~* Any significant current medical conditions~* Women who are peri- and post- menopausal, pregnant or lactating~* MRI specific exclusion criteria (e.g., claustrophobia, implanted metal in the body)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Alcohol use disorder with early trauma (Type: OTHER): Individuals with alcohol use disorder participated in an equivalent 8-week outpatient treatment program.
- Alcohol use disorder without early trauma (Type: OTHER): Individuals with alcohol use disorder participated in an equivalent 8-week outpatient treatment program.
- Controls with early trauma (Type: NO_INTERVENTION): Control participants did not receive any treatment.
- Controls without early trauma (Type: NO_INTERVENTION): Control participants did not receive any treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-assisted Versus Conventional Landmark-guided Paramedian Spinal Anesthesia in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients (age≥60 years) scheduled to undergoing elective orthopedic surgery under spinal anesthesia~* Patients with ASA physical status classification I, II, III~Exclusion Criteria:~* Patients with contraindication to spinal anesthesia (coagulopathy, local infection, allergy to local anesthetic)~* Patients with morbid cardiac diseases~* Pregnancy~* Patients with previous history of lumbar spine surgery

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound-assisted (Type: EXPERIMENTAL): Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
- Landmark-guided (Type: ACTIVE_COMPARATOR): In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria include:~* clinically significant tinnitus according to the initial score on the Tinnitus and Hearing Survey (THS) (minimum total score of 4 on section A; if score is 4-6, one item must be at least 3);~* demonstrates understanding of the requirements of the study (based on adequate responses to the questions by the RC that assess capacity-to-consent);~* has had a hearing test within the past 2 years (and was fitted with hearing aids if appropriate); and~* motivated and capable of participating (including ability to communicate over the telephone in English).~Exclusion Criteria:~* Callers who do not meet all of these criteria will be excluded from study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tele-PTM (Type: EXPERIMENTAL): Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
- Wait List Control (Type: OTHER): Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C infection defined as positive anti-HCV antibodies and serum HCV-RNA \>1000 IU/ml, naive to antiviral treatment~* age \>18 years~Exclusion Criteria:~* Antidepressive treatment within the last 3 years~* Psychiatric diseases including major depressive disorders in past medical history~* Active substance abuse during the last 12 months~* Pregnancy, lactation, wish to become pregnant~* Hepatitis B (HBV)/HIV-coinfection~* Decompensated liver disease, hepatocellular carcinoma, history of bleeding esophageal varices~* Neutropenia (\<1500/ul), thrombocytopenia (\<70/nl), anemia (\<12g/dl in females, \<13g/dl in males)~* History of autoimmune disease~* History of organ transplantation, concomitant liver disease, severe cardiopulmonary disease, hemolytic anemia, malignant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
- Placebo (Type: PLACEBO_COMPARATOR): After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible to participate in the study extension, by definition, will have met the inclusion and exclusion criteria for the core 26 weeks and not met the withdrawal criteria for the core study B2335S at Visit 14 (the last visit of the core study B2335S and the first visit of the extension study B2335SE).~* In addition the following inclusion/exclusion criteria specified below must be met.~  1. Patients must complete Stage 2 of the core study B2335S (NCT00463567).~ 2. Written informed consent to participate in the extension must be obtained.~ 3. Patients must be able to comply with all study requirements.~Exclusion Criteria:~* Patients who were randomized to open-label tiotropium in Study B2335S.~* Patients who participated in Stage 1 of the core study (B2335S).~* Patients discontinued irrespective of the reason from Stage 2 of the core study.~* Patients who fail to comply with the core protocol requirements and procedures.~* Concomitant medical conditions that may interfere with interpretation of study results as defined in the core study protocol.~* Patients who in the Investigator's opinion should not participate in the extension study.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 µg (Type: EXPERIMENTAL): Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.
- Indacaterol 300 µg (Type: EXPERIMENTAL): Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete